Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis

NCT01065727 is registered in ClinicalTrials.gov with Rennes University Hospital as lead sponsor.

NCT NCT01065727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01065727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis
Lead sponsor
Rennes University Hospital
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2010
Completion date
November 30, 2023
Enrollment
144 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis